$XBIO
Xenetic Biosciences, Inc.

2022 Q4 Form 10-Q Financial Statement

#000168316822007447 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $487.0K $414.3K $349.3K
YoY Change 46.41% 18.6% 191.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $857.2K $863.2K $945.1K
YoY Change -12.32% -8.66% 18.14%
% of Gross Profit
Research & Development $1.193M $398.8K $780.2K
YoY Change -2.92% -48.88% 36.87%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $2.050M $1.262M $1.725M
YoY Change -7.08% -26.85% 25.02%
Operating Profit -$847.8K -$1.376M
YoY Change -38.39%
Interest Expense $79.81K $45.48K $28.03K
YoY Change 171.09% 62.25% 40.15%
% of Operating Profit
Other Income/Expense, Net $990.00 $43.77K -$2.910K
YoY Change -65.86% -1604.09%
Pretax Income -$1.483M -$804.0K -$1.351M
YoY Change -19.5% -40.48% -87.11%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.483M -$804.0K -$1.351M
YoY Change -19.5% -40.48% -82.13%
Net Earnings / Revenue -304.44% -194.09% -386.77%
Basic Earnings Per Share -$0.06 -$0.13
Diluted Earnings Per Share -$0.10 -$0.06 -$132.9K
COMMON SHARES
Basic Shares Outstanding 15.17M shares 14.32M shares 10.16M shares
Diluted Shares Outstanding 14.32M shares 10.16M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.10M $13.85M $19.70M
YoY Change -28.21% -29.71% 179.47%
Cash & Equivalents $13.10M $13.85M $19.70M
Short-Term Investments
Other Short-Term Assets $556.1K $319.1K $878.2K
YoY Change 16.0% -63.67% -6.57%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.65M $14.17M $20.58M
YoY Change -27.08% -31.16% 157.58%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.067M $1.406M $704.4K
YoY Change -2.29% 99.57% 0.63%
Total Long-Term Assets $1.067M $1.406M $704.4K
YoY Change -2.29% 99.57% -0.78%
TOTAL ASSETS
Total Short-Term Assets $13.65M $14.17M $20.58M
Total Long-Term Assets $1.067M $1.406M $704.4K
Total Assets $14.72M $15.57M $21.29M
YoY Change -25.71% -26.84% 144.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $287.4K $202.8K $248.5K
YoY Change -20.72% -18.4% -0.6%
Accrued Expenses $785.8K $848.1K $873.0K
YoY Change -25.77% -2.86% 61.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.073M $1.051M $1.122M
YoY Change -24.48% -6.3% 41.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.073M $1.051M $1.122M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.073M $1.051M $1.122M
YoY Change -24.48% -6.3% 41.96%
SHAREHOLDERS EQUITY
Retained Earnings -$189.1M -$187.6M
YoY Change 3.59%
Common Stock $15.19K $14.34K
YoY Change 12.83%
Preferred Stock
YoY Change
Treasury Stock (at cost) $5.281M $5.281M
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity $13.65M $14.52M $20.16M
YoY Change
Total Liabilities & Shareholders Equity $14.72M $15.57M $21.29M
YoY Change -25.71% -26.84% 144.66%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$1.483M -$804.0K -$1.351M
YoY Change -19.5% -40.48% -82.13%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$750.9K -$1.079M -$1.033M
YoY Change -48.52% 4.44% 2.31%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$500.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $11.45M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 11.45M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -750.9K -1.079M -1.033M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 0.000 11.45M
Net Change In Cash -750.9K -1.079M 10.42M
YoY Change -48.52% -110.36% -1131.8%
FREE CASH FLOW
Cash From Operating Activities -$750.9K -$1.079M -$1.033M
Capital Expenditures $0.00 -$500.0K
Free Cash Flow -$750.9K -$579.3K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001534525
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
xbio Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
usd
CY2021Q3 xbio Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
usd
CY2021Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
usd
xbio Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37937
dei Entity Registrant Name
EntityRegistrantName
XENETIC BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2952962
dei Entity Address Address Line1
EntityAddressAddressLine1
945 Concord Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Framingham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01701
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
778-7720
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15166596 shares
CY2022Q3 us-gaap Cash
Cash
13848172 usd
CY2021Q4 us-gaap Cash
Cash
18244030 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
319103 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
479399 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
14167275 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
18723429 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1405851 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1091931 usd
CY2022Q3 us-gaap Assets
Assets
15573126 usd
CY2021Q4 us-gaap Assets
Assets
19815360 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
202778 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
362470 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
848080 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1058633 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1050858 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1421103 usd
CY2022Q3 us-gaap Liabilities
Liabilities
1050858 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1421103 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
14342 usd
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14343587 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13466603 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14316596 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13439612 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13465 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
207149681 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
205952729 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-187617083 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182547265 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2022Q3 us-gaap Treasury Stock Value
TreasuryStockValue
5281180 usd
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
5281180 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
14522268 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18394257 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15573126 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19815360 usd
CY2022Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
414250 usd
CY2021Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
349269 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1219953 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
828088 usd
CY2022Q3 us-gaap Revenues
Revenues
414250 usd
CY2021Q3 us-gaap Revenues
Revenues
349269 usd
us-gaap Revenues
Revenues
1219953 usd
us-gaap Revenues
Revenues
828088 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
398803 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
780153 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3577701 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1934432 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
863233 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
945115 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2796832 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2766397 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
1262036 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
1725268 usd
us-gaap Operating Expenses
OperatingExpenses
6374533 usd
us-gaap Operating Expenses
OperatingExpenses
4700829 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-847786 usd
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
28029 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1375999 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5154580 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3872741 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1706 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2906 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2583 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1784 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
45475 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
87345 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
71026 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
43769 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25123 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
84762 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
69242 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-804017 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1350876 usd
us-gaap Net Income Loss
NetIncomeLoss
-5069818 usd
us-gaap Net Income Loss
NetIncomeLoss
-3803499 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14316596 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14316596 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10162167 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10162167 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13944286 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13944286 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9223560 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9223560 shares
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15188921 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
137364 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-804017 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
14522268 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18394257 usd
xbio Issuance Of Common Stock In Connection With Purchase Of Inprocess Research And Development
IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopment
805000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
392829 usd
us-gaap Net Income Loss
NetIncomeLoss
-5069818 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
14522268 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
9949107 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11450866 usd
CY2021Q3 xbio Exercise Of Prefunded Warrants
ExerciseOfPrefundedWarrants
3679 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
111131 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1350876 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
20163907 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
12215524 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11450866 usd
xbio Exercise Of Prefunded Warrants
ExerciseOfPrefundedWarrants
3679 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
297337 usd
us-gaap Net Income Loss
NetIncomeLoss
-3803499 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
20163907 usd
us-gaap Net Income Loss
NetIncomeLoss
-5069818 usd
us-gaap Net Income Loss
NetIncomeLoss
-3803499 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1305000 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
27043 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
26199 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
392829 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
297337 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-133253 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
62484 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
313920 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-105555 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-370245 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
157524 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3895858 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3279368 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
500000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
-0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-500000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11450866 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3679 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11454545 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4395858 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8175177 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18244030 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11527552 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13848172 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19702729 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
xbio Issuance Of Common Stock To Acquire Inprocess Research And Development
IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment
805000 usd
xbio Issuance Of Common Stock To Acquire Inprocess Research And Development
IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment
0 usd
xbio Issuance Of Common Stock To Vendor
IssuanceOfCommonStockToVendor
0 usd
xbio Issuance Of Common Stock To Vendor
IssuanceOfCommonStockToVendor
7 usd
xbio Issuance Of Common Stock From Cashless Exercise Of Purchase Warrants
IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants
2 usd
xbio Issuance Of Common Stock From Cashless Exercise Of Purchase Warrants
IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants
4 usd
CY2022Q3 us-gaap Payments For Fees
PaymentsForFees
300000 usd
CY2022Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
300000 usd
CY2022Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
850000 shares
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
137364 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
111131 usd
us-gaap Share Based Compensation
ShareBasedCompensation
392829 usd
us-gaap Share Based Compensation
ShareBasedCompensation
297337 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32800000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31400000 usd
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
27043 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
26199 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36326 usd
CY2022Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0 usd
CY2021Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 usd
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
36326 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd

Files In Submission

Name View Source Status
0001683168-22-007447-index-headers.html Edgar Link pending
0001683168-22-007447-index.html Edgar Link pending
0001683168-22-007447.txt Edgar Link pending
0001683168-22-007447-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbio-20220930.xsd Edgar Link pending
xenetic_ex3101.htm Edgar Link pending
xenetic_ex3102.htm Edgar Link pending
xenetic_ex3201.htm Edgar Link pending
xenetic_i10q-093022.htm Edgar Link pending
xbio-20220930_def.xml Edgar Link unprocessable
xbio-20220930_lab.xml Edgar Link unprocessable
xbio-20220930_pre.xml Edgar Link unprocessable
xenetic_i10q-093022_htm.xml Edgar Link completed
xbio-20220930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable